Artwork

Content provided by CEimpact. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CEimpact or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Is the Price Right for Aducanumab?

37:22
 
Share
 

Manage episode 298425432 series 2931422
Content provided by CEimpact. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CEimpact or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The first new treatment for Alzheimer's, aducanumab, was approved by the Food and Drug Administration on June 7, 2021. This approval did not come without controversy. Learn what the available data show for efficacy and safety and whether or not the current list price of $56,000 per year meets cost-effectiveness thresholds.
Guest
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad
Redeem your CPE or CME credit here!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Aducanumab for Alzheimer's Disease: Effectiveness and Value. Institute for Clinical and Economic Review. June 30, 2021. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Revised_Evidence_Report_06302021.pdf
Continuing Education Information:
Learning Objectives:
1. Discuss the outcomes for phase III trials of aducanumab
2. Define the cost-effectiveness of aducanumab
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-265-H01-P
Initial release date: 7/27/21
Expiration date: 7/27/22
John A. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

  continue reading

268 episodes

Artwork
iconShare
 
Manage episode 298425432 series 2931422
Content provided by CEimpact. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CEimpact or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The first new treatment for Alzheimer's, aducanumab, was approved by the Food and Drug Administration on June 7, 2021. This approval did not come without controversy. Learn what the available data show for efficacy and safety and whether or not the current list price of $56,000 per year meets cost-effectiveness thresholds.
Guest
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad
Redeem your CPE or CME credit here!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Aducanumab for Alzheimer's Disease: Effectiveness and Value. Institute for Clinical and Economic Review. June 30, 2021. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Revised_Evidence_Report_06302021.pdf
Continuing Education Information:
Learning Objectives:
1. Discuss the outcomes for phase III trials of aducanumab
2. Define the cost-effectiveness of aducanumab
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-265-H01-P
Initial release date: 7/27/21
Expiration date: 7/27/22
John A. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

  continue reading

268 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide